Volume 32, No 12, Dec 2022

ISSN: 1001-0602 
EISSN: 1748-7838  
2020 impact factor 25.617*  
(Clarivate Analytics, 2021)

About the cover

A proteogenomic study reclassified pituitary neuroendocrine tumors into seven subtypes. Each subtype has specific potential treatment targets, which is summarized as the tree in the image. This new, treatment-oriented classification represents a breakthrough for selecting appropriate therapeutic interventions for this highly heterogeneous disease. See page 1047–1067 by Fan Zhang et al. for details.

Advanced Online Publication: 3 Nov 2022

LETTERS TO THE EDITOR

Molecular recognition of itch-associated neuropeptides by bombesin receptors

Read more

Current Issue: Vol.32 (Dec 2022)

EDITORIAL

Sanofi-Cell Research outstanding paper award of 2021

RESEARCH HIGHLIGHTS

Off-the-shelf CAR T cells to treat cancer
Sustaining plant immunity in rising temperature
The scent of a microbe: how host viral infection increases mosquito attraction
Live cold to grow old? Thermogenesis to fight cancer
A type III-E CRISPR Craspase exhibiting RNase and protease activities

ORIGINAL ARTICLES

Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity
Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia

LETTERS TO THE EDITOR

AI-empowered integrative structural characterization of m6A methyltransferase complex
Cryo-EM structure of the type III-E CRISPR-Cas effector gRAMP in complex with TPR-CHAT

CORRIGENDA

Author Correction: Gut microbiota drives macrophage-dependent self-renewal of intestinal stem cells via niche enteric serotonergic neurons
Correction: CRISPR FISHer enables high-sensitivity imaging of nonrepetitive DNA in living cells through phase separation-mediated signal amplification